Post-chemotherapy response of paclitaxel and carboplatin regimens in advanced stage cervical cancer types of histopathology squamous cell carcinoma and adenocarcinoma

Abstract

Background: Cervical cancer incidence in South Borneo was placed 10th in Indonesia. South Borneo Department of Health revealed 1,930 patients diagnosed with cervical cancer in 2019. The main therapy for advanced cervical cancer was radiotherapy, chemotherapy, and combination. This study aims to demonstrate that paclitaxel plus carboplatin regimens have a better post-chemotherapy response in patients with advanced cervical cancer squamous cell carcinoma than adenocarcinoma.

Methods: This study used an analytical observational method with a cross-sectional approach. The sample size was taken during the period during which this study was conducted from January 2015 to December 2020 and was taken by total sampling and divided into 2 groups consisting of patients with advanced cervical cancer, squamous cell carcinoma, and adenocarcinoma histological types. Data were analyzed using SPSS version 21.0 for Windows.

Results: A total of 202 individuals made up the study's sample, including 54 (26.8%) adenocarcinomas, 148 (73.2%) patients with advanced cervical cancer, and patients with various histological kinds of squamous cell carcinoma. About 107 (52.9%) patients provided complete responses, whereas up to 95 (47.1%) patients provided incomplete responses.

Conclusion: Squamous cell carcinoma, the histological type of cervical cancer, responds to treatment better than adenocarcinoma.